Davern Capital Partners, LP
Follow13F filer, CIK 2003147, NY, NY
Davern Capital Partners, LP reported $586,539,478 across 15 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-13. Its ten largest share positions make up 86.76% of the portfolio.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000905148-26-003614
- Period
- 2026-06-30
- Reported value
- $587M
- Holdings
- 15
- Top 10 weight
- 86.76%
- New
- 3
- Sold out
- 5
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| BNTXadded | +449,495 | $41.8M |
| INSMadded | +377,262 | $40.2M |
| ROIVadded | +1,059,506 | $37.5M |
| RPRXadded | +635,800 | $35.6M |
| ALNYnew | +113,085 | $34M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| PFEexited | -1,593,942 | -$44.8M |
| ARGXexited | -35,045 | -$25.6M |
| LLYexited | -27,279 | -$25.1M |
| ABVXexited | -78,125 | -$8.7M |
| NTRAreduced | -24,991 | -$6.78M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q2 2026
Share positions as resolved from 13F-HR 0000905148-26-003614, largest first. % of portfolio is the value over $586,539,478, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| BNTXBIONTECH SE | 754,550 | $70.2M | 11.97% | +449,495 | Timeline | ||
| ROIVROIVANT SCIENCES LTD | 1,932,904 | $68.4M | 11.66% | +1,059,506 | Timeline | ||
| RPRXROYALTY PHARMA PLC | 1,155,809 | $64.8M | 11.05% | +635,800 | Timeline | ||
| IONSIONIS PHARMACEUTICALS INC | 798,709 | $63.3M | 10.8% | +411,806 | Timeline | ||
| INSMINSMED INC | 559,824 | $59.7M | 10.18% | +377,262 | Timeline | ||
| REGNREGENERON PHARMACEUTICALS | 92,640 | $57.8M | 9.85% | +47,840 | Timeline | ||
| LEGNLEGEND BIOTECH CORP | 1,191,522 | $34.4M | 5.87% | -123,226 | Timeline | ||
| ALNYALNYLAM PHARMACEUTICALS INC | 113,085 | $34M | 5.8% | new | Timeline | ||
| NTRANATERA INC | 118,975 | $32.3M | 5.51% | -24,991 | Timeline | ||
| GPCRSTRUCTURE THERAPEUTICS INC | 446,059 | $23.9M | 4.08% | +319,598 | Timeline | ||
| MLYSMINERALYS THERAPEUTICS INC | 858,753 | $23.2M | 3.95% | +411,600 | Timeline | ||
| VERAVERA THERAPEUTICS INC | 498,832 | $21.4M | 3.65% | new | Timeline | ||
| GENBGENERATE BIOMEDICINES INC | 824,679 | $13.9M | 2.37% | +232,879 | Timeline | ||
| PRCTPROCEPT BIOROBOTICS CORP | 464,920 | $10.5M | 1.79% | +203,720 | Timeline | ||
| AVTXAVALO THERAPEUTICS INC | 468,666 | $8.66M | 1.48% | new | Timeline |
Sold out in Q2 2026
Positions in the previous quarter's report that this quarter's report no longer lists.
How Q2 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000905148-26-003614 | base | 2026-08-13 | acceptance time not in the bulk data set |
Filings
Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000905148-26-003614 | Quarter ended 2026-06-30 | 2026-08-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000905148-26-002267 | Quarter ended 2026-03-31 | 2026-05-14 | acceptance time not in the bulk data set | |
| 13F-HR 0000905148-26-000704 | Quarter ended 2025-12-31 | 2026-02-13 | acceptance time not in the bulk data set |